<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30367451</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1097-0215</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>International journal of cancer</Title>                <ISOAbbreviation>Int. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Cost-effectiveness of Breast Cancer Screening Programme for Women in Rural China.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/ijc.31956</ELocationID>            <Abstract>                <AbstractText>In low and middle-income countries mammographic breast cancer screening is prohibitively expensive and a cheaper alternative option is to use ultrasound as the primary screening test. In 2009, China launched a breast cancer screening programme for rural women aged 35-64 years with clinical breast examination coupled with ultrasound as the primary tool. This study aimed to analyse the cost-effectiveness of breast screening compared with no screening among Chinese rural women. We developed a Markov model to estimate the lifetime costs and effects for rural women aged 35 years from a societal perspective. Asymptomatic women in the intervention arm were screened every three years before age 64 years. Breast cancer in the non-screening arm can only be diagnosed on presentation of symptoms. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses. Compared to no screening, breast cancer screening cost $186.7 more and led to a loss of 0.20 quality-adjusted life years (QALYs). Breast screening was more expensive and did harm to health among rural women with an incremental cost-effectiveness ratio (ICER) of $-916/QALY. The sensitivity analysis identified utility loss from false positives as the factor that most influenced the results, but this did not affect the conclusions. In a rural setting with such low incidence, screening for asymptomatic disease is not cost-effective with current screening tools. Priority should be given to ensure that symptomatic women have proper access to diagnosis and treatment at an early stage as this will lead to mortality reductions without the usual screening harms. This article is protected by copyright. All rights reserved.</AbstractText>                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Li</ForeName>                    <Initials>L</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5569-7296</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>School of Public Health, Peking University, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sadique</LastName>                    <ForeName>Zia</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dos-Santos-Silva</LastName>                    <ForeName>Isabel</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Li</ForeName>                    <Initials>L</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0640-2003</Identifier>                    <AffiliationInfo>                        <Affiliation>School of Public Health, Peking University, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Legood</LastName>                    <ForeName>Rosa</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Int J Cancer</MedlineTA>            <NlmUniqueID>0042124</NlmUniqueID>            <ISSNLinking>0020-7136</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">China</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">cost-effectiveness</Keyword>            <Keyword MajorTopicYN="N">rural</Keyword>            <Keyword MajorTopicYN="N">screening</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30367451</ArticleId>            <ArticleId IdType="doi">10.1002/ijc.31956</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>